Treating Infectious Diseases: Lessons from COVID-19 and Avoiding Future Pandemics

With more than 20 million infections of COVID-19 across the globe and no approved treatments, the biotech industry has learned a great deal about innovation, adapting business practices, and collaboration. BIO’s COVID-19 Therapeutic Development Tracker Data shows the rapid pursuit of treatments with 698 unique active compounds in development, many of them by small biotech companies. With the race to treatment underway, there are many lessons learned from the current pandemic. Hear from companies, investors, and public health experts on changes in business practices, immediate recommendations, and plans for the future.